Previous 10 | Next 10 |
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the pricing of its previously announced initial public off...
In a $480 million deal, Zenas, a Shanghai-Boston biopharma, acquired global rights to a bifunctional antibody from Xencor that targets CD19. Beijing's BeiGene closed on a 42-acre US site in the Princeton, NJ area where it will build a manufacturing center and house clinical R&D op...
BeiGene will become the world’s first stock to be simultaneously listed in the U.S., Hong Kong and on one of China’s A-share markets. Some analysts believe that a strong valuation for BeiGene’s new A-share listing could help to boost its stock price in the U.S. an...
BeiGene (NASDAQ:BGNE) announces that the European Commission (EC) has approved Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of patients unsuit...
EU approval follows recent approvals for BRUKINSA including U.S., China, Brazil, and Canada The approval is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the Europea...
Beigene (NASDAQ:BGNE) has closed on a 42-acre site in Hopewell, N.J. where it will build a manufacturing facility and clinical R&D center. The manufacturing facility is expected to have 400,000 square feet of space. Construction of the initial phase is expected to begin next year and comp...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the commencement of an initial public offering (STAR Offer...
BeiGene plans to develop 42-acre site at Princeton West Innovation Park in Hopewell, New Jersey as a manufacturing site for advanced new medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative c...
BeiGene (NASDAQ:BGNE) announces that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways impli...
Expanding portfolio with first internally discovered asset in Inflammation and Immunology with internally discovered asset A highly selective, allosteric TYK2 inhibitor that has shown potent inhibition against pro-inflammatory cytokines in preclinical studies BeiGene...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...